[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341742-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341742-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-and-validation-of-stc1-act-as-a-biomarker-for-high-altitude-diseases-and-its-pan-cancer-analysis","Identification and Validation of STC1 Act as a Biomarker for High-Altitude Diseases and Its Pan-Cancer Analysis","","High-altitude diseases, including acute mountain sickness, high-altitude cerebral edema, and high-altitude pulmonary edema, are tightly linked to hypoxic adaptation capacity. The study evaluates STC1 as a biomarker by combining gene-expression analyses with functional experiments and assessing STC1 expression, mutation, and diagnostic performance across cancer datasets. STC1 shows marked differential expression across 13 malignant tumor types, correlates with prognosis, and modulates tumor immunity via six immune-cell groups. GEO validation and qPCR confirmation support computational findings, suggesting STC1’s relevance to both altitude adaptation and cancer low-oxygen responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-and-validation-of-stc1-act-as-a-biomarker-for-high-altitude-diseases-and-its-pan-cancer-analysis/341742/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-and-validation-of-stc1-act-as-a-biomarker-for-high-altitude-diseases-and-its-pan-cancer-analysis/341742.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main objective regarding STC1?","Question",{"text":63,"@type":64},"To identify and validate STC1 as a key gene/biomarker related to high-altitude diseases and to characterize its expression patterns in cancer. It also examines diagnostic and prognostic relevance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was STC1 evaluated in the research?",{"text":68,"@type":64},"The study uses gene expression data analysis plus functional experiments, then performs expression and mutation analyses across multiple cancer samples. It validates results using GEO datasets and qPCR testing.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study suggest about STC1’s role in cancer and immunity?",{"text":72,"@type":64},"STC1 expression differs significantly across 13 malignant tumor types and is associated with patient prognosis. It influences tumor immunity by mediating six immune-cell types in the tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341742,1790792238,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nIdentification and Validation of STC1 Act as a Biomarker for High-Altitude Diseases and Its Pan-Cancer Analysis  \nQiong Li 1,2, Zhichao Xu 1,2, Qianhui Gong 1,2 and Xiaobing Shen 1,2, *  \nCitation: Li, Q.; Xu, Z.; Gong, Q.; Shen, X. Identification and Validation of STC1 Act as a Biomarker for  \nHigh-Altitude Diseases and Its Pan-Cancer Analysis. Int. J. Mol. Sci. 2024, 25, 9085. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25169085](10.3390/ijms25169085)  \nAcademic Editors: Consolato M. Sergi, Angelo Ravelli and Luca Pio  \nReceived: 26 July 2024  \nRevised: 19 August 2024  \nAccepted: 20 August 2024  \nPublished: 21 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210003, China; [joan_tiny@163.com](joan_tiny@163.com) (Q.L.); [xuzhichao_24@163.com](xuzhichao_24@163.com) (Z.X.); [gongqh2717@163.com](gongqh2717@163.com) (Q.G.)  \n2 Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210003, China  \n* Correspondence: [xb.shen@seu.edu.cn](xb.shen@seu.edu.cn)  \nAbstract: High-altitude diseases, including acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE), are closely related to an individual’s ability to adapt to hypoxic environments. However, specific research in this field is relatively limited, and further biomarker research and clinical trials are needed to clarify the exact role and potential therapeutic applications of key genes in high-altitude diseases. This study focuses on the role of the STC1 gene in high-altitude diseases and explores its expression patterns in different types of cancer. By using gene expression data analysis and functional experiments, we identified STC1 as a key gene affecting the development of altitude sickness. In addition, we also conducted expression and mutation analysis on STC1 in various cancer samples and found significant differences in the expression of this gene in 13 types of malignant tumors, which is associated with the hypoxic state in the tumor microenvironment. In addition, STC1 is significantly associated with patient prognosis and influences tumor immunity by mediating six types of immune cells (CD8+T cells, CD4+T cells, neutrophils, macrophages, monocytes, and B cells) in the tumor microenvironment. The expression and diagnostic value of STC1 were confirmed through GEO datasets and qPCR testing, indicating consistency with the results of bioinformatics analysis. These results indicate that STC1 is not only an important factor in the adaptive response to high-altitude diseases but may also play a role in the adaptation of cancer to low-oxygen environments. Our research provides a new perspective and potential targets for the discovery of biomarkers for high-altitude diseases and cancer treatment.  \nKeywords: STC1; high-altitude disease; pan-cancer; tumor microenvironment; immune infiltration  \n1. Introduction  \nAcclimatization in high-altitude environments is a complex and crucial process. However, at altitudes exceeding 2500 m, the reduced oxygen content can cause the rapid onset of high-altitude diseases in individuals from lowland areas who have not adapted [1] . High-altitude illnesses, such as acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE), are common physiological responses to the low oxygen conditions at high altitudes. These illnesses lead to internal imbalances in several physiological systems, including the brain, lungs, a","cbCaiubxrHW8mVNs","https://ap.wps.com/l/cbCaiubxrHW8mVNs","pdf",6414362,22,"English","# Introduction\n## Hypoxia and immune regulation in high-altitude illness\n## HIF-mediated molecular mechanisms\n## Inflammation and immune adaptation at high altitude","[{\"question\":\"What is the study’s main objective regarding STC1?\",\"answer\":\"To identify and validate STC1 as a key gene/biomarker related to high-altitude diseases and to characterize its expression patterns in cancer. It also examines diagnostic and prognostic relevance.\"},{\"question\":\"How was STC1 evaluated in the research?\",\"answer\":\"The study uses gene expression data analysis plus functional experiments, then performs expression and mutation analyses across multiple cancer samples. It validates results using GEO datasets and qPCR testing.\"},{\"question\":\"What does the study suggest about STC1’s role in cancer and immunity?\",\"answer\":\"STC1 expression differs significantly across 13 malignant tumor types and is associated with patient prognosis. It influences tumor immunity by mediating six immune-cell types in the tumor microenvironment.\"}]","Identification and Validation of STC1 Act as a Biomarker for High-Altitude Diseases and Its Pan-Cancer Analysis | PDF",1790043493,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63e5d603f99bdb1ca2098f3a18296304.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d29a449e4431867e44babad98e167bc.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f47ce94f4c14f5f82f3675628e59b304.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd206c9bce363af7c6b3c43c4bdb4598.webp",980,1385]